PN400

DRUG8 trials

Sponsors

POZEN, AstraZeneca

Conditions

ArthritisHealthyHealthy VolunteerPlatelet Inhibition

Phase 1

PK Study to Evaluate Esomeprazole Plasma Levels Following Administration of PN 400

CompletedNCT00599404

Start: 2008-01-31End: 2008-02-29Updated: 2008-04-30

Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations

CompletedNCT00665743

Start: 2008-03-31End: 2008-06-30Target: 30Updated: 2008-06-10

Study Evaluating the Effect of Food on the Bioavailability of PN400 Components

CompletedNCT00676442

Start: 2008-05-31End: 2008-06-30Updated: 2008-09-05

Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations

CompletedNCT00692055

Start: 2008-06-30End: 2008-07-31Updated: 2008-09-05

Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E

CompletedNCT00761501

AstraZenecaHealthy Volunteer

Start: 2008-09-30End: 2008-12-31Target: 38Updated: 2010-12-09

Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Naprosyn E

CompletedNCT00907400

AstraZenecaHealthy

Start: 2009-05-31End: 2009-09-30Target: 48Updated: 2010-12-10

Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone

CompletedNCT00992381

AstraZenecaHealthy

Start: 2009-09-30End: 2009-10-31Target: 24Updated: 2010-01-18

A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin

CompletedNCT01094483

AstraZenecaPlatelet Inhibition

Start: 2010-03-31End: 2010-05-31Target: 40Updated: 2010-12-07

Related Papers

Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.

2011-11-1011 citations